Summary: In a small double-blind randomized clinical pharmacology trial of 61 adults with obesity, once-daily oral semaglutide dose-escalated to 50 mg reduced ad libitum energy intake at week 20 by a between-group relative difference of -39.2 percentage points (95% CI -59.0, -19.4) versus placebo, alongside a 9.8% body-weight reduction (vs 1.5% with placebo). No statistically significant difference in gastric emptying was observed.
PICO Summary
| Element | Detail |
|---|---|
| Population | 61 adults living with obesity; double-blind, placebo-controlled clinical pharmacology randomized trial; treatment country not specified in the report. |
| Intervention | Once-daily oral semaglutide, dose-escalated to 50 mg, for 20 weeks (semaglutide arm of the randomized cohort). |
| Comparison | Once-daily matching placebo over the same 20-week period (placebo arm of the randomized cohort). |
| Outcome | Primary endpoint (relative change from baseline in ad libitum energy intake at week 20): -39.2 percentage points (95% CI -59.0, -19.4) with semaglutide versus placebo. Body weight reduced 9.8% with semaglutide versus 1.5% with placebo (no CI or p value reported in the abstract). Reduced hunger, increased fullness and satiety, fewer food cravings, and better control of eating versus placebo. Gastric emptying (paracetamol absorption): no statistically significant difference at week 20. ARR/NNT not applicable to these continuous outcomes. |
Oral semaglutide 50 mg: energy intake & appetite
RCT · obesity · 20 weeks
Oral semaglutide 50 mg cut ad libitum energy intake by 39 percentage points versus placebo and lowered body weight, with no delayed gastric emptying, supporting a central appetite mechanism. Small sample limits precision.
Expert Commentary
This is a small, double-blind, placebo-controlled clinical pharmacology trial designed to probe the appetite mechanisms of oral semaglutide rather than to establish weight-loss efficacy at scale. Within those limits, the signal is coherent: ad libitum energy intake fell by a between-group relative difference of -39.2 percentage points (95% CI -59.0, -19.4), appetite ratings improved across hunger, fullness, satiety, and cravings, and body weight dropped 9.8% versus 1.5% with placebo. The accompanying gastric-emptying result was null, which is mechanistically useful because it argues that reduced intake reflects central appetite suppression rather than delayed stomach emptying at this stage. The chief limitation is statistical fragility: with only 61 randomized participants the energy-intake confidence interval is wide, and the body-weight contrast is reported without a confidence interval or p value, so it should be read as descriptive. Funding and authorship sit with the manufacturer, and an open-label dose history within a blinded design warrants the usual caution about sponsor-favourable framing. Can I use this with my patients? Not yet as a basis for prescribing 50 mg oral semaglutide, since this dose and indication require confirmation in adequately powered phase-3 outcome trials, but the mechanistic reassurance on appetite is informative. Larger pre-registered efficacy and safety data should guide practice.
References
Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, Adrian CL. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial. Diabetes Obes Metab. 2024;26(10):4480-4489. doi:10.1111/dom.15802